Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410752 | 0.88 | ALPL (0.36) | ALDH1A1ALPLHSD17B10MAPK1CYP3A4 | |
| SCHEMBL5417695 | 0.83 | AURKA (0.41) | ALDH1A1ALPLHSD17B10MAPK1CYP3A4 | |
| SCHEMBL6407392 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAPTPN1RECQLAURKA | |
| SCHEMBL3629414 | 0.78 | HSD17B10 (0.51) | ALDH1A1ALPLHSD17B10MAPK1CYP3A4 | |
| SCHEMBL7236120 | 0.75 | ALDH1A1 (0.41) | ALDH1A1ALPLLMNAHSD17B10 | |
| SCHEMBL6767802 | 0.67 | ALPL (0.39) | ALDH1A1ALPLLMNAHSD17B10MAPK1 | |
| SCHEMBL6692185 | 0.67 | CDK4 (0.33) | LMNA | |
| SCHEMBL1220108 | 0.66 | HSD17B10 (0.42) | ALDH1A1ALPLHSD17B10MAPK1CYP3A4 | |
| SCHEMBL7667971 | 0.65 | HSD17B10 (0.43) | ALDH1A1ALPLHSD17B10MAPK1CYP3A4 | |
| SCHEMBL6773177 | 0.64 | MAPT (0.52) | ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | ALDH1A1 3457/4885ALPL 2767/4885LMNA 2012/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | ALDH1A1 2196/4885ALPL 3762/4885LMNA 3031/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | ALDH1A1 2442/4885ALPL 1712/4885LMNA 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.